X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2443) 2443
Publication (311) 311
Newsletter (270) 270
Newspaper Article (121) 121
Book Review (85) 85
Magazine Article (66) 66
Book / eBook (62) 62
Book Chapter (42) 42
Conference Proceeding (21) 21
Trade Publication Article (17) 17
Dissertation (6) 6
Web Resource (5) 5
Government Document (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pharmacogenetics (2543) 2543
humans (1812) 1812
index medicus (1248) 1248
pharmacology & pharmacy (846) 846
pharmacogenomics (536) 536
research (518) 518
genotype (409) 409
female (383) 383
pharmacogenetics - methods (363) 363
genomics (341) 341
personalized medicine (340) 340
drugs (333) 333
male (327) 327
genetic aspects (311) 311
analysis (309) 309
genetics (299) 299
cancer (283) 283
medicine (276) 276
drug therapy (261) 261
pharmacogenetics - economics (254) 254
pharmacology (249) 249
pharmacogenetics - trends (242) 242
care and treatment (229) 229
precision medicine (228) 228
genetics & heredity (223) 223
adult (222) 222
middle aged (221) 221
united states (220) 220
health aspects (203) 203
article (195) 195
treatment outcome (179) 179
genetic screening (178) 178
animals (177) 177
therapy (177) 177
cost-benefit analysis (171) 171
polymorphism (168) 168
warfarin (168) 168
medical research (167) 167
association (164) 164
genetic testing (163) 163
psychiatry (163) 163
pharmaceutical industry (162) 162
aged (155) 155
usage (155) 155
patients (151) 151
biomarkers (150) 150
polymorphism, single nucleotide (149) 149
cost-effectiveness (146) 146
polymorphism, genetic (146) 146
risk factors (146) 146
genetic variation (144) 144
genes (143) 143
polymorphisms (139) 139
reports (138) 138
genetic research (137) 137
medicine & public health (132) 132
drug design (129) 129
pharmacokinetics (128) 128
risk (126) 126
metabolism (125) 125
clinical trials (122) 122
phenotype (121) 121
medicine, experimental (120) 120
oncology (118) 118
genomes (113) 113
studies (109) 109
economic aspects (106) 106
genetic polymorphisms (105) 105
methods (105) 105
precision medicine - methods (105) 105
cytochrome p-450 (104) 104
genome-wide association (103) 103
medicine, general & internal (102) 102
pharmacy (102) 102
disease (100) 100
genetic predisposition to disease (100) 100
abridged index medicus (97) 97
drug development (96) 96
biotechnology & applied microbiology (94) 94
ethics (94) 94
physiological aspects (94) 94
review (94) 94
breast-cancer (90) 90
forecasts and trends (90) 90
internal medicine (89) 89
neurosciences (89) 89
adolescent (87) 87
management (86) 86
aryl hydrocarbon hydroxylases - genetics (85) 85
genetic testing - economics (85) 85
gene (84) 84
dose-response relationship, drug (83) 83
enzymes (81) 81
mutation (81) 81
biochemistry & molecular biology (80) 80
algorithms (79) 79
chemotherapy (79) 79
genome, human (79) 79
population (79) 79
medicine, research & experimental (78) 78
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (22) 22
Online Resources - Online (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
UofT at Mississauga - Stacks (4) 4
UofT at Scarborough - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Periodical Stacks (1) 1
Gerstein Science - Reference (1) 1
May be requested (1) 1
Providence Healthcare - Stacks (1) 1
UTL at Downsview - Pharmacy (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2962) 2962
French (17) 17
German (13) 13
Japanese (7) 7
Spanish (5) 5
Portuguese (4) 4
Italian (2) 2
Russian (2) 2
Chinese (1) 1
Danish (1) 1
Dutch (1) 1
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 01/2013, Volume 11, Issue 1, pp. 81 - 91
Background:  The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary... 
clopidogrel | cost‐effectiveness | prasugrel | antiplatelet therapy | genetic testing | acute coronary syndromes | Antiplatelet therapy | Prasugrel | Clopidogrel | Genetic testing | Acute coronary syndromes | Cost-effectiveness | cost-effectiveness | LAST YEAR | CYP2C19 GENOTYPE | TREATED PATIENTS | BYPASS GRAFT-SURGERY | ATRIAL-FIBRILLATION | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | OF-CARE | CLINICAL-OUTCOMES | Prasugrel Hydrochloride | Predictive Value of Tests | Thiophenes - therapeutic use | Percutaneous Coronary Intervention - mortality | Acute Coronary Syndrome - economics | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Thiophenes - metabolism | Medicare - economics | Models, Economic | Pharmacogenetics - economics | Time Factors | Ticlopidine - economics | Myocardial Infarction - etiology | Insurance, Health, Reimbursement - economics | Quality-Adjusted Life Years | Genetic Predisposition to Disease | Risk Assessment | Gene Frequency | Risk Factors | Piperazines - therapeutic use | Ticlopidine - analogs & derivatives | Phenotype | Acute Coronary Syndrome - therapy | Thrombosis - genetics | Percutaneous Coronary Intervention - economics | Percutaneous Coronary Intervention - adverse effects | Thrombosis - economics | Drug Costs | Platelet Aggregation Inhibitors - economics | Markov Chains | Ticlopidine - therapeutic use | United States | Acute Coronary Syndrome - mortality | Piperazines - economics | Piperazines - metabolism | Computer Simulation | Hemorrhage - etiology | Ticlopidine - metabolism | Thiophenes - economics | Platelet Aggregation Inhibitors - metabolism | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Decision Support Techniques | Kaplan-Meier Estimate | Treatment Outcome | Cerebrovascular Disorders - etiology | Aryl Hydrocarbon Hydroxylases - metabolism | Disease-Free Survival | Health Care Costs | Cytochrome P-450 CYP2C19 | Cost-Benefit Analysis | Acute Coronary Syndrome - diagnosis | Acute Coronary Syndrome - genetics | Genetic Testing - economics | Transluminal angioplasty | Care and treatment | Medicare | Analysis | Cardiac patients | Cytochrome P-450 | Markov processes | Cost benefit analysis | Coronary heart disease | Genetic screening | Angina pectoris | Genotype & phenotype
Journal Article
2008, ISBN 1847870481, 715
With escalating healthcare costs, changes to the regulatory control on pharmaceutical industries and the inevitable adjustments made in policies and investment... 
Medical care | Medical economics | Medical technology
Book
Seminars in Nuclear Medicine, ISSN 0001-2998, 09/2019, Volume 49, Issue 5, pp. 450 - 457
Nuclear medicine has come a long way since 2007 when Adrian Nunn pointed out the approval of radiopharmaceuticals was at an all-time low with all the major... 
ANTIBODY J591 | MEMBRANE ANTIGEN | THERAPY | PHARMACOKINETICS | BIODISTRIBUTION | CANCER | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | PRINCIPLES | DISCOVERY | STRATEGIES | SMT487 | Drugs | Drug delivery systems | Usage | Pharmacogenetics | Drug discovery | Pharmaceutical industry | Drug approval | Vehicles | RADIOLOGY AND NUCLEAR MEDICINE
Journal Article
pharmacogenomics journal, ISSN 1470-269X, 2016, Volume 16, Issue 5, pp. 478 - 484
We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and... 
Drug Costs | Predictive Value of Tests | Markov Chains | Anticoagulants - administration & dosage | Humans | Anticoagulants - economics | Precision Medicine - economics | Warfarin - adverse effects | Male | Warfarin - economics | Models, Economic | Pharmacogenomic Testing - economics | Warfarin - administration & dosage | Patient Selection | Pharmacogenetics - economics | Atrial Fibrillation - economics | Drug Dosage Calculations | Sweden | Pharmacogenomic Variants | Female | Atrial Fibrillation - diagnosis | International Normalized Ratio - economics | Vitamin K Epoxide Reductases - genetics | Quality-Adjusted Life Years | Atrial Fibrillation - drug therapy | Treatment Outcome | United Kingdom | Anticoagulants - adverse effects | Atrial Fibrillation - genetics | Cytochrome P-450 CYP2C9 - genetics | Randomized Controlled Trials as Topic | Cost-Benefit Analysis | Quality of Life | Aged | Drug Monitoring - economics | Warfarin | Pharmacogenetics | Atrial fibrillation | Analysis | Economic aspects | Dosage and administration | Research | Drug therapy | Medical care, Cost of | Hälsovetenskaper | Health Care Service and Management, Health Policy and Services and Health Economy | Medical and Health Sciences | Medicin och hälsovetenskap | Health Sciences | Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi
Journal Article
AIDS, ISSN 0269-9370, 2008, Volume 22, Issue 15, pp. 2025 - 2033
Objective: To evaluate the clinical impact and cost-effectiveness of HLA-B*5701 testing to guide selection of first-line HIV regimens in the United States.... 
Genetic testing | HIV | Cost-effectiveness | Antiretroviral therapy | Abacavir | cost-effectiveness | INFECTIOUS DISEASES | SAFETY | antiretroviral therapy | EMTRICITABINE | TENOFOVIR DF | IMMUNOLOGY | COMBINATION | CARE | VIROLOGY | NAIVE PATIENTS | genetic testing | PHARMACOGENOMICS | EFAVIRENZ | ABACAVIR HYPERSENSITIVITY REACTION | abacavir | COHORT | Anti-HIV Agents - economics | Drug Hypersensitivity - prevention & control | HIV Infections - economics | Humans | Middle Aged | Male | Genetic Testing - methods | Adenine - economics | Dideoxynucleosides - economics | Pharmacogenetics - economics | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Drug Costs - statistics & numerical data | Adenine - therapeutic use | Sensitivity and Specificity | Antiretroviral Therapy, Highly Active - economics | Drug Hypersensitivity - genetics | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | HLA-B Antigens - genetics | Drug Hypersensitivity - etiology | Quality-Adjusted Life Years | Organophosphonates - economics | Adenine - analogs & derivatives | Drug Hypersensitivity - economics | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - genetics | Treatment Outcome | Models, Biological | Cost-Benefit Analysis | Health Care Costs - statistics & numerical data | HIV Infections - drug therapy | Genetic Testing - economics | Index Medicus | AIDS/HIV
Journal Article
04/2019, National Bureau of Economic Research Conference Report, ISBN 9780226611068, 361
This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug... 
Pharmacogenetics | Personalized medicine-Economic aspects-United States | Personalized medicine
eBook
Journal Article
Value in Health, ISSN 1098-3015, 2012, Volume 15, Issue 8, pp. 1162 - 1171
Journal Article